subject: The Market Outlook For Neurodegenerative Diseases: Epidemiology, Market Size, Current Treatments [print this page] Each year over 10 million people globally suffer from neurodegenerative diseases (ND). This figure is expected to grow by 20% over the next decade as the aging population increases and lives longer. Such population growth translates to an expanded therapeutic market for key NDs, including Alzheimers, Parkinsons, multiple sclerosis, Huntingtons, and amyotrophic lateral sclerosis because of increased prevalence, associated medical treatment costs, and demand for more effective new treatments. In a highly competitive environment, understanding the market dynamics of the ND therapy area is crucial for product development to enable benchmarking and strategic planning in context of the pipeline and established market forces.
In a sector currently estimated at reaching $20bn by 2014, long-term sustainable growth opportunities in ND are anticipated based on increasing diagnoses of these disorders, increased genericization, and novel late-stage products and technologies.
This report explores novel therapeutics that show promise to widen the therapeutic options for ND and also highlights the key commercialisation activities and developments of major players.
This report hence offers essential market insight on the research and development trends for the ND area providing a rapid understanding of current therapeutics, their advantages and disadvantages, and the important pipeline candidates most likely to succeed in the marketplace. Additionally, this report provides a comprehensive assessment of current and future pharmacological and novel cell-based treatments for these diseases and updates the reader on pathophysiology, epidemiology, pipeline research, product evaluations, and commercial opportunities. The report also outlines the key drivers and inhibitors of drug development in each sector with detailed analysis based on primary and secondary research.
Key features of this report
In-depth analyses of disease epidemiology, pathobiology, products, pipelines, and commercial opportunities in neurodegenerative diseases
Evaluation of the R&D clusters and themes in ND drug development.
Identifies the current trends in product and clinical development.
Detailed assessment of leading products in Alzheimers disease, amyotrophic lateral sclerosis, Huntingtons disease, multiple sclerosis, and Parkinsons disease.
Analysis of novel cell therapies for ND and how they may impact on traditional drug development
Comprehensive coverage of drug classes currently marketed and in the pipeline for major NDs
Market analysis of current and future therapy areas to 2014
Identification and evaluation of leading products and market opportunities in neurodegenerative diseases
Therapy area forecasts and sector opportunities in an increasingly competitive landscape.
Key benefits from reading this report
Understand the basis to NDs and key prevalence and aetiology data driving drug development
Up-to-date information on products, activities, and companies driving innovations in the field.
Shows how drug development is progressing and the risks involved in developing drugs for NDs
Identifies product successes and failures and details current sales for leading drugs with forecasts to 2014 for established and pipeline candidates
Provides analyses and commentary on trends in research, clinical development, and marketing activities of products.
Enables rapid assessment of the scope of activity in the field and how innovations may radically change the face of therapeutics in the next 5-10 years.
Shows forecasts of leading products and new entrants to market to enable product positioning and scenario building
Provides market insight on the current and future landscape for ND treatments.
To know more about this report & to buy a copy please visit :
